| HOME >> BIOLOGY >> TECHNOLOGY |
LA JOLLA, Calif., April 30, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Bruce Carter, Ph.D. to its Board of Directors. Dr. Carter currently serves as an independent member of the Board of Directors of Immune Design Corp., a privately held biotech company located in Seattle, and as a board member of additional scientific organizations. He previously served as Chief Executive Officer of Zymogenetics, Inc. and has over 20 years of pharmaceutical and biotech drug development experience.
"We are delighted to have Bruce join our Board," said John Maraganore, Ph.D., Chairman of the Board of Directors of Regulus Therapeutics Inc. "His impressive credentials and sound business judgment will further enhance our Board's collective expertise."
"Regulus' mature therapeutic platform targeting microRNAs, coupled with its world-renowned scientific advisors and experienced leadership team, make joining the Board an exciting opportunity for me," said Dr. Carter. "I look forward to service on the Board as Regulus drives multiple programs toward the clinic."
Dr. Carter joined Immune Design Corp. in November 2009 and served as Executive Chairman of the Board until May 2011, and Chairman of the Board until February 2012. He still serves as an independent Director. In addition to his duties at Immune Design, Dr. Carter serves as Chairman of the Board of the TB Alliance, a worldwide nonprofit organization based in New York City, and Xencor, Inc., in Pasadena, California. He also serves as a Board member for Dr. Reddy, Ltd. located in Hyderabad, India and QLT, Inc. of Vancouver, B.C., Canada.
Prior to joining Regulus' Board of Directors, Dr. Carter was a member of the management team at ZymoGenetics, Inc. where he held vari
'/>"/>
| SOURCE Regulus Therapeutics Inc. Copyright©2010 PR Newswire. All rights reserved |
Related biology technology :
1. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
2. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
3. Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
4. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
5. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
6. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
7. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
8. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
9. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
10. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
11. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |